# Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT07108699** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** HSK39004 Dry Powder Inhaler-0.75mg
- **DRUG:** HSK39004 Dry Powder Inhaler-1.5mg
- **DRUG:** HSK39004 Dry Powder Inhaler Simulant

## Key facts

- **NCT ID:** NCT07108699
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-13
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07108699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07108699, "Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07108699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*